| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 42.30 | 0.06 (+0.14%) | 33.51 - 44.44 | 283.0 thousand (Below Avg) |
Market data as of 4:01PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 42.44 |
|---|---|
| Previous Close | 42.24 |
| Day's Range | 42.05 - 42.48 |
| Market Cap | 2.2B |
| Avg Volume (10 Day) | 317.8K |
| Price/Earnings (Trailing 12 Mo.) | 57.1x |
| Earnings Per Share (Trailing 12 Mo.) | 0.74 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Invitations to Investors Conferences and Annual Report Filings - Research Report on Haemonetics, Insulet, DexCom, HeartWare, and Mindray
PR Newswire - Tuesday 06/11/2013 8:00 AM ET
Haemonetics to Present at The William Blair 33rd Annual Growth Stock Conference
PR Newswire - Wednesday 06/05/2013 8:00 AM ET
Haemonetics And SABM Announce Research Grant
PR Newswire - Wednesday 05/29/2013 8:00 AM ET
Haemonetics to Present at The Jefferies 2013 Global Healthcare Conference
PR Newswire - Friday 05/24/2013 4:00 PM ET
Haemonetics to Present at The Deutsche Bank 38th Annual dbAccess Health Care Conference
PR Newswire - Thursday 05/23/2013 4:39 PM ET
| HAE | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 22.55% | |
| Net Income Growth (1yr) | -41.99% | |
| Total Debt/Equity | 0.62 | |
| LT Debt/Equity | 0.59 | |
| Earnings Yield | 1.75% | |
| Price/Sales | 2.42 |
| Company | Last | Change |
|---|---|---|
| Hill-Rom Holdings Inc | 35.19 | -0.37% |
| West Pharmaceutical Services Inc | 67.66 | +0.59% |
| Thoratec Corp | 32.06 | +0.41% |
| Insulet Corp | 30.78 | +1.15% |
| DexCom Inc | 22.56 | +1.85% |
Data is delayed by at least 15 min.